DISEASE STATE / MECHANISM OF ACTION
ASSET
NO. GENE TARGETS
REGULATORY PATHWAY
IP
STATUS
NEXT STEPS
Vascular Dementia
VNDMA
3
medicinal
Patent
potential
R&D
FTO & patentability identified. Next steps IP & biomanufacturing.
depression
(moderate)
serokind™
10
medicinal
pat pending
trademark
Phase I Clinical
Phase I trial designed with the University of Edinburgh. Patent Application written. Next step biomanufacturing
depression
(mild)
serotonin metabolite
2
-
data
Proof of Concept
Medical Research Council - SSRI comparison study with the University of Manchester
Anhedonia
dopamine metabolite
3
-
data
Proof of Concept
Gene cluster to disease severity analysis
Memory
acetylcholine metabolite
5
-
data
Proof of Concept
Gene cluster to disease severity analysis
Cognition
dopamine precursor
1
-
data
Proof of Concept
Vascular Dementia
Asset
VNDMA
Gene Targets
3
Pathway
medicinal
IP
Patent
potential
Status
R&D
Next Steps
FTO & patentability identified. Next steps IP & biomanufacturing.
depression
(moderate)
Asset
serokind™
Gene Targets
10
Pathway
medicinal
IP
pat pending
trademark
Status
Phase I Clinical
Next Steps
Phase I trial designed with the University of Edinburgh. Patent Application written. Next step biomanufacturing
depression
(mild)
Asset
serotonin metabolite
Gene Targets
2
Pathway
-
IP
data
Status
Proof of Concept
Next Steps
Medical Research Council - SSRI comparison study with the University of Manchester
Anhedonia
Asset
dopamine metabolite
Gene Targets
3
Pathway
-
IP
data
Status
Proof of Concept
Next Steps
Gene cluster to disease severity analysis
Memory
Asset
acetylcholine metabolite
Gene Targets
5
Pathway
-
IP
data
Status
Proof of Concept
Next Steps
Gene cluster to disease severity analysis
Cognition
Asset
dopamine precursor
Gene Targets
1
Pathway
-
IP
data
Status
Proof of Concept